SK Biopharmaceuticals First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

SK Biopharmaceuticals (KRX:326030) First Quarter 2025 Results

Key Financial Results

• Revenue: ₩144.4b (up 27% from 1Q 2024).
• Net income: ₩23.3b (up 82% from 1Q 2024).
• Profit margin: 16% (up from 11% in 1Q 2024). The increase in margin was driven by higher revenue.
• EPS: ₩298 (up from ₩164 in 1Q 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

SK Biopharmaceuticals EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 11%.

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in South Korea.

Performance of the South Korean Pharmaceuticals industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

You still need to take note of risks, for example - SK Biopharmaceuticals has 1 warning sign we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.